- NovoCure (NVCR) is scheduled to announce Q2 earnings results on Thursday, July 23rd, before market open.
- The consensus EPS Estimate is -$0.33 and the consensus Revenue Estimate is $172.44M (+8.6% Y/Y).
- Over the last 1 year, NVCR has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time.
- Over the last 3 months, EPS estimates have seen 5 upward revisions and 2 downward. Revenue estimates have seen 4 upward revisions and 3 downward.
More on NovoCure
- NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026
- NovoCure: Solid Fundamentals, But TRIDENT Caps Near-Term Upside
- NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet
- Novocure falls after late-stage trial setback for cancer treatment device
- Novocure outlines $690M-$710M 2026 revenue guidance as Optune Pax launch reaches 169 prescriptions in 7 weeks